Navigation Links
Animal Research Uncovers Another Mechanism of Cholesterol Lowering Drug

New research in animals suggests why the commonly prescribed cholesterol-lowering drug ezetimibe (Zetia) is so potent. The research, reported by scientists at Wake Forest University School of Medicine, is reported online today by the Journal of Clinical Investigation and will appear in the July 2 print issue.

It had previously been thought that the drug works by preventing cells in the intestine from absorbing cholesterol. The new research suggests that Zetia also works in the liver. In both locations, the drugs target is a protein known as NPC1L1 that moves cholesterol into the bodys cells. Zetia blocks the proteins actions so cholesterol cannot be absorbed.

Cholesterol comes not only from the foods we eat, but is also produced by the liver. The organ is involved in making cholesterol, as well as in taking up cholesterol and packaging it for the bodys use.

We know that this protein that the drug targets is expressed not only in the intestine, but is abundant in the human liver, said Ryan E. Temel, Ph.D., lead author. The scientists made the discovery about Zetias dual action by studying mice that were specially engineered to produce NPC1L1 in the liver.

When there were high levels of the protein in the liver, which enhanced cholesterol absorption by the cells, there was a drastic reduction in cholesterol levels in the bile. But when the mice were treated with Zetia, the cholesterol levels returned to normal, suggesting that the drug targets NPC1L1 in the liver.

These findings suggest that in humans, the drug may reduce cholesterol levels in the blood by inhibiting NPC1L1 function in both the intestine and liver, said Liqing Yu, M.D., Ph.D., senior researcher and an assistant professor of pathology, Section on Lipid Sciences.

The researchers theorize that when Zetia blocks this process in the liver, the cholesterol that cannot be absorbed is secreted into bile, the digestive juices that are stored in the gallbladder. Normally, most of biliary cholesterol is secreted from the body in the feces. However, when the bile contains too much cholesterol, gallstones can result. These hardened pieces of cholesterol can block the passageway from the gallbladder to the intestine, resulting in severe abdominal pain, liver damage and nutrient malabsorption.

The fact that Zetia works in two locations is positive because it makes it more effective as a cholesterol-lowering drug, said Temel. But our research suggests the potential for having too much cholesterol in the bile, which could possibly cause gallstones.

The researchers hope to study the question in monkeys and said more research is needed to see if the drug increases gallstone formation in some people. Until more research is done in animal models that naturally express the protein, it is difficult to say whether this would apply to humans, said Yu.


'"/>




Related medicine news :

1. Animal Fat Enhances Risk Of Stomach
2. Cancer hazard Found With Animal-Based Nutrients
3. Animal Fat increases risk Of stomach cancer
4. Animal insulin product to be discontinued by drug major Eli Lilly
5. Animals Can give us a second chance at life
6. Animals can give us a second chance at life
7. SARS vaccine shows promise in Animal Testing
8. Kidneys Can Be Transplanted From Animals Such As Pigs In Future
9. Broccoli Found to Block Cancer Progression In Both Animal and Human Studies
10. Animal Cruelty free Test Kit
11. Increase in the Number of Cases of Animal Diseases in New South Wales.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2016)... ... 05, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Tasting Event at the La Gorce Country Club in Miami Beach on March ...
(Date:2/5/2016)... ... 2016 , ... Regular gym users know the routine: each January, they see ... the treadmills. It’s a predictable trend. After the excesses of November and December, people ... by joining gyms, starting new walking or running routines, or signing up for Zumba. ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... (APDA) announced the election of Patrick McDermott as Chairman of the National Board of ... welcome Pat as Chairman of the Board,” stated Leslie A. Chambers , APDA ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... Move from on one drop zone to the next using Colorize's dynamic moving camera. ... any project. This package includes a 3D slideshow environment with 1 to 5 focus ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... for Patients with Rare Diseases, a continuing medical education (CME) event presented by ... first of its kind—and a first for ACCORD, whose mission is to provide ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... , Feb. 4, 2016 Summary ... common cancer and the most common cancer in women ... the disease exceedingly prevalent. The number of women diagnosed ... decades, but the number of deaths has declined due ... cancer treatment has been revolutionized in the past four ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
Breaking Medicine Technology: